{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:20:18Z","timestamp":1794442818393,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1245\/s10434-025-17991-6","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T15:39:34Z","timestamp":1754321974000},"page":"7215-7227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis"],"prefix":"10.1245","volume":"32","author":[{"given":"Yawen","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Santol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Podrascanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel A. Kankeu","family":"Fonkoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rondell P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin B.","family":"Conboy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne G.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P.","family":"Starlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"17991_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101290","volume":"7","author":"Z Li","year":"2025","unstructured":"Li Z, Aliseda D, Jones O, et al. Recent advances in systemic therapy for advanced biliary tract cancer: a systematic review and meta-analysis using reconstructed RCT survival data. JHEP Rep. 2025;7:101290. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101290.","journal-title":"JHEP Rep."},{"key":"17991_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med."},{"key":"17991_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694\u2013704. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"17991_CR4","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet."},{"key":"17991_CR5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/archsurg.1993.01420200045008","volume":"128","author":"DM Nagorney","year":"1993","unstructured":"Nagorney DM. Outcomes after curative resections of cholangiocarcinoma. Arch Surg. 1993;128:871. https:\/\/doi.org\/10.1001\/archsurg.1993.01420200045008.","journal-title":"Arch Surg."},{"key":"17991_CR6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5:824\u201330. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0270.","journal-title":"JAMA Oncol."},{"key":"17991_CR7","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","volume":"30","author":"SK Maithel","year":"2023","unstructured":"Maithel SK, Keilson JM, Cao HST, et al. NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023;30:6558\u201366. https:\/\/doi.org\/10.1245\/s10434-023-13809-5.","journal-title":"Ann Surg Oncol."},{"key":"17991_CR8","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","volume":"29","author":"MC de Jong","year":"2011","unstructured":"de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140\u20135. https:\/\/doi.org\/10.1200\/JCO.2011.35.6519.","journal-title":"J Clin Oncol."},{"key":"17991_CR9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/archsurg.2012.1962","volume":"147","author":"D Ribero","year":"2012","unstructured":"Ribero D, Pinna AD, Guglielmi A, et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch Surg. 2012;147:1107\u201313. https:\/\/doi.org\/10.1001\/archsurg.2012.1962.","journal-title":"Arch Surg."},{"key":"17991_CR10","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.2012.41.5984","volume":"31","author":"Y Wang","year":"2013","unstructured":"Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188\u201395. https:\/\/doi.org\/10.1200\/JCO.2012.41.5984.","journal-title":"J Clin Oncol."},{"key":"17991_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jamasurg.2013.5168","volume":"149","author":"O Hyder","year":"2014","unstructured":"Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014;149:432\u20138. https:\/\/doi.org\/10.1001\/jamasurg.2013.5168.","journal-title":"JAMA Surg."},{"key":"17991_CR12","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. U.S. Department of Health and Human Services, National Institutes of Health. Published 27 November 2017. Retrieved 7 May 2025 at https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"17991_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1365-182X(17)30755-4","volume":"2","author":"SM Strasberg","year":"2000","unstructured":"Strasberg SM, Belghiti J, Clavien PA, et al. The Brisbane 2000 terminology of liver anatomy and resections. HPB. 2000;2:333\u20139. https:\/\/doi.org\/10.1016\/S1365-182X(17)30755-4.","journal-title":"HPB."},{"key":"17991_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg."},{"key":"17991_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, et al. The clavien-dindo classification of surgical complications. Ann Surg. 2009;250:187\u201396. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b13ca2.","journal-title":"Ann Surg."},{"key":"17991_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.surg.2010.10.001","volume":"149","author":"NN Rahbari","year":"2011","unstructured":"Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713\u201324. https:\/\/doi.org\/10.1016\/j.surg.2010.10.001.","journal-title":"Surgery."},{"key":"17991_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1245\/s10434-017-6025-x","volume":"25","author":"YS Chun","year":"2018","unstructured":"Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25:845\u20137. https:\/\/doi.org\/10.1245\/s10434-017-6025-x.","journal-title":"Ann Surg Oncol."},{"key":"17991_CR18","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1097\/PAS.0000000000000738","volume":"40","author":"SM Lee","year":"2016","unstructured":"Lee SM, Katz MHG, Liu L, et al. Validation of a proposed tumor regression grading scheme for pancreatic ductal adenocarcinoma after neoadjuvant therapy as a prognostic indicator for survival. Am J Surg Pathol. 2016;40:1653\u201360. https:\/\/doi.org\/10.1097\/PAS.0000000000000738.","journal-title":"Am J Surg Pathol."},{"key":"17991_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2214\/AJR.09.4110","volume":"195","author":"M Nishino","year":"2010","unstructured":"Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010;195:281\u20139. https:\/\/doi.org\/10.2214\/AJR.09.4110.","journal-title":"AJR Am J Roentgenol."},{"key":"17991_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO-24-01383","volume":"43","author":"RT Shroff","year":"2025","unstructured":"Shroff RT, King G, Colby S, et al. SWOG S1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol. 2025;43:536\u201344. https:\/\/doi.org\/10.1200\/JCO-24-01383.","journal-title":"J Clin Oncol."},{"key":"17991_CR21","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","volume":"16","author":"R Dienstmann","year":"2011","unstructured":"Dienstmann R, Bra\u00f1a I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist. 2011;16:1729\u201340. https:\/\/doi.org\/10.1634\/theoncologist.2011-0163.","journal-title":"Oncologist."},{"key":"17991_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100787","volume":"8","author":"V Amoroso","year":"2023","unstructured":"Amoroso V, Gallo F, Alberti A, et al. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors\u2019 efficacy: a systematic review and meta-analysis of randomized studies. ESMO Open. 2023;8:100787. https:\/\/doi.org\/10.1016\/j.esmoop.2023.100787.","journal-title":"ESMO Open."},{"key":"17991_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/jso.23762","volume":"110","author":"B Groot Koerkamp","year":"2014","unstructured":"Groot Koerkamp B, Fong Y. Outcomes in biliary malignancy. J Surg Oncol. 2014;110:585\u201391. https:\/\/doi.org\/10.1002\/jso.23762.","journal-title":"J Surg Oncol."},{"key":"17991_CR24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.surg.2022.09.028","volume":"173","author":"SH Choi","year":"2023","unstructured":"Choi SH, Kang I, Lee SH, et al. Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. Surgery. 2023;173:280\u20138. https:\/\/doi.org\/10.1016\/j.surg.2022.09.028.","journal-title":"Surgery."},{"key":"17991_CR25","doi-asserted-by":"publisher","first-page":"175883592110359","DOI":"10.1177\/17588359211035983","volume":"13","author":"J Cheon","year":"2021","unstructured":"Cheon J, Lee CK, Sang YB, et al. Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis. Ther Adv Med Oncol. 2021;13:17588359211035984. https:\/\/doi.org\/10.1177\/17588359211035983.","journal-title":"Ther Adv Med Oncol."},{"key":"17991_CR26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12885-024-12225-6","volume":"24","author":"M Niger","year":"2024","unstructured":"Niger M, Nichetti F, Fornaro L, et al. A phase II\/III randomized clinical trial of CisPlatin plUs gemcitabine and nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study. BMC Cancer. 2024;24:436. https:\/\/doi.org\/10.1186\/s12885-024-12225-6.","journal-title":"BMC Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17991-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17991-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17991-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:04:35Z","timestamp":1758549875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17991-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["17991"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17991-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nguyen H. Tran has received funding or has served as consultant (directed to Mayo Clinic Foundation) for AstraZeneca, DAVA oncology, Elevar, Exact Sciences, Exelixis, Genentech, Ipsen, and QED\/Helsinn Therapeutics. Dr. Tran\u2019s research is supported by the National Institute of Minority Health and Health Disparity K23 Career Development Grant (K23MD017217-01A1). The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}